Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02791191 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 316
- Enrollment target
NCT02791191 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 316 participants.
The verdict
NCT02791191, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 316 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
Interventions
- DRUG Placebo
- DRUG LY3202626
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2016-06-16 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02791191
The ClinicalTrials.gov registry entry for NCT02791191 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02791191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02791191 about?
NCT02791191 is a clinical study titled "A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia". The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
What is the current status of trial NCT02791191?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 316 participants. The study started on 2016-06-16. Estimated completion is 2018-07-02.
What interventions are being tested in trial NCT02791191?
The interventions under investigation include: Placebo (DRUG), LY3202626 (DRUG).
Who is sponsoring clinical trial NCT02791191?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.